Moderna's XFG-Targeting COVID-19 Vaccine Wins Singapore HSA Authorization
核心洞察
Singapore's Health Sciences Authority (搜索) has authorised Moderna's Spikevax XFG (搜索), an updated mRNA COVID-19 (搜索) vaccine targeting the SARS-CoV-2 XFG variant (搜索), for active immunisation.
Spikevax XFG (搜索) is the first COVID-19 (搜索) vaccine against the JN.1-lineage XFG variant authorised by HSA in Singapore, effective 18 August 2026.
European and U.S. regulators named XFG the preferred JN.1-lineage variant for 2026-2027 updated vaccines, and WHO said XFG-targeting formulations may be used with evidence of strong immune response.
Moderna Singapore said the Health Sciences Authority (搜索) (HSA) has authorised Spikevax XFG (搜索), its updated COVID-19 (搜索) mRNA vaccine targeting the SARS-CoV-2 XFG variant (搜索), for active immunisation against COVID-19 in Singapore. The authorisation, dated 18 August 2026, makes Spikevax XFG the first COVID-19 vaccine targeting the JN.1-lineage XFG variant to be authorised by HSA for use in Singapore.
The vaccine uses mRNA technology to instruct cells to produce the virus's spike protein so the immune system can recognise it and build a response. XFG, a JN.1-lineage variant, has been predominant globally in recent months. For 2026-2027, European and U.S. regulators identified XFG as the preferred JN.1-lineage variant for updated vaccines, while the World Health Organization has said XFG-targeting formulations may be used when supported by evidence of a strong immune response against currently circulating variants.
In Singapore, Spikevax XFG (搜索) is approved as a multidose vial for individuals aged six months and older and as a pre-filled syringe for those aged 12 years and older. COVID-19 (搜索) vaccination continues to be recommended for people at increased risk of severe illness, including those aged 60 and above, medically vulnerable individuals aged six months and above, and aged-care facility residents; healthcare workers and those living or working with medically vulnerable people are also encouraged to consider vaccination.
Source: biopharmaapac.com